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Marketa Hecht-Dolnik, MD,a Howard Barkan, DrPH,b Ananse Taharka, MD,a and John Loftus, MDa
Objective:Hetastarch is an artificial colloid widely used intraoperatively in fluid-replacement regimens. Previous
studies have found that the intraoperative administration of hetastarch may increase the risk of postoperative
bleeding in patients who undergo coronary artery bypass graft surgery with cardiopulmonary bypass. Previous
published reports have not examined this risk in patients who underwent coronary artery bypass grafting without
cardiopulmonary bypass.
Methods: In a randomized clinical trial, 156 patients undergoing off-pump coronary artery bypass grafting were
assigned to receive either 1 liter of hetastarch or 1 liter of albumin as part of intraoperative volume replacement.
Sample recruitment was halted in a review per protocol by the study’s Data Safety Monitoring Committee. We as-
sessed the rate of postoperative bleeding bymonitoring the number of units of blood products transfused in the first
24 postoperative hours in the intensive care unit and thehourly chest tube drainage in thefirst 12 postoperativehours.
Results: Intraoperative administration of 1 liter of hetastarch was associated with statistically significant in-
creases in 3 measures: transfusion requirements on postoperative day 1 (red blood cells, 1.14 vs 0.40 units,
P ¼ .017; fresh-frozen plasma, 0.57 vs 0.15, P ¼ .009; platelets, 0.35 vs 0.10, P ¼ .013); the overall likelihood
of receiving transfusion on postoperative day 1 (46.2% vs 25.6%, P ¼ .012); and the volume of chest tube
drainage in the first 12 hours postoperatively (732.0 vs 563.6 mL, P< .001).
Conclusion: In patients undergoing off-pump coronary artery bypass, the intraoperative administration of hetas-
tarch increases the postoperative transfusion requirement and the volume of blood drained postoperatively.P
MPostoperative bleeding is a major concern in coronary artery
bypass graft (CABG) surgery. High-molecular-weight hy-
droxyethyl starch 6% (hetastarch) in a buffered electrolyte
dextrose solution is an inexpensive artificial colloid now
widely used as part of perioperative fluid-replacement regi-
mens. There is now active debate1-14 about whether the use
of hetastarch for fluid replacement in CABG adds to the risk
of postoperative bleeding.3,4,7,15 The debate has been fueled
by inconsistent study results from individual studies.3,9-12
Analyses have noted inconsistencies among the studies
and sample size and other methodological limitations of
the individual previous experimental and nonexperimental
studies.3,9,10,15-17 Variations in fluid replacement and opera-
tive protocol over the times when these source studies were
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doi:10.1016/j.jtcvs.2009.02.035The Journal of Thoracic and Cconducted limit their generalizability to the current practice
environment.1,4,18-21 The question of the excess bleeding
risk carried by hetastarch was settled for patients undergoing
CABG by a case-control study1 that found a dose-dependent
association between postoperative bleeding and intraopera-
tive use of hetastarch.
A high proportion, approximately 85% of the CABG
procedures at our facility, and an increasing proportion of
procedures performed at other facilities in the United States
are conducted off pump (off-pump coronary artery bypass
[OPCAB]).22,23 The ‘‘pump effect’’ on coagulation and
other hemodynamic factors mean that findings regarding
the risk of postoperative bleeding and other outcomes that
have been obtained for CABG performed on pump may
not apply to OPCAB performed off pump.10,24-26 As such,
it is unclear whether a fluid now widely used for volume re-
placement in a common operation carries an increased risk
of a major untoward outcome when that fluid is used in
this operation.
We report the results of a randomized clinical trial de-
signed to evaluate the effect of intraoperative administration
of hetastarch on postoperative bleeding in patients who un-
derwent OPCAB in an active cardiac surgery practice. Our
study was designed to investigate the association of intrao-
perative hetastarch administration with the risk of postoper-
ative bleeding in OPCAB. Our results will have important
implications regarding the safety of hetastarch use in
OPCAB as it is performed in regular clinical practice.1,5ardiovascular Surgery c Volume 138, Number 3 703
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BMI ¼ body mass index
CABG ¼ coronary artery bypass graft
DSMC ¼ Data and Safety Monitoring Committee
FDR ¼ false discovery rate
ICU ¼ intensive care unit
INR ¼ international normalized ratio
OPCAB ¼ off-pump coronary artery bypass
POD ¼ postoperative day
METHODS AND MATERIALS
Eligibility
We screened for eligibility all adult Kaiser Permanente members who
were admitted to Alta Bates Summit Medical Center (Oakland, CA) be-
tween September 1, 2004, and July 27, 2005, for planned OPCAB. We ob-
tained informed consent to participate preoperatively from screened patients
whomet the study eligibility criteria.We excluded pregnant patients and pa-
tients with a history of cardiac surgery, primary bleeding disorders, or end-
stage renal disease from participation. This study design was reviewed and
approved by institutional review boards of The Permanente Medical Group
and the Alta Bates Summit Medical Center.
Statistical Power Analysis
Wedesigned our power analysis for evaluation of the equivalence of a re-
sult in the study and control groups, defining a zone of equivalence for the
statistical power analysis rather than basing our power analysis on the more
usual clinically significant difference. We used volume of packed cells
transfused within the first 24 hours postoperatively as the target outcome
for the statistical power analysis. This outcome is routinely measured and
reliably available from previous studies. We used the results published
for one of the previous randomized trials8 as the basis for the specific
hypotheses evaluated in our calculation of statistical power. Despite some
design differences between our study and that conducted by Sade and
colleagues,8 we based the statistical hypotheses on the results of their study
because those results included the measurements of the amount of blood
products transfused and the amount of chest tube drainage postoperatively
in patients after CABG needed to conduct our power calculations. We in-
vestigated whether patients in whom hetastarch instead of albumin was
used as a part of intraoperative colloid replacement received an equivalent
amount of postoperative blood products in the first 24 hours postopera-
tively. We calculated statistical power using the confidence interval-based
technique for normally distributed interval variables.27 Sade and col-
leagues8 report that patients receiving albumin as priming fluid for
CABG received 358 (standard deviation ¼ 396) mL packed cells in the
postoperative period ending 7:00 A.M. on postoperative day (POD) 1. We
defined the range of equivalence asþ100 mL and set the confidence interval
at 95%. Power analysis indicated that a target sample size of 165 patients in
each arm of the study (hetastarch and albumin) was needed to give our study
a 90% statistical power to achieve a result that is statistically significant.
We used block randomization with 8 patients in each block to ensure
that the maximum size of the difference between the study and the control
groups would be 4 if the study were halted at any time before the full
sample size had been recruited. We randomly assigned 156 consecutive
patients to receive either 6% hetastarch or 5% albumin in the periopera-
tive period (cf. discussion of sampling below). Randomization assign-
ments were ordered by study number. The assignments were recorded
on paper slips that were placed in opaque envelopes. Each envelope
was coded by study number and sealed. The attending anesthesiologist
opened the envelope linked to the patient’s study number in the operating704 The Journal of Thoracic and Cardiovascular Surroom when the procedure was under way and administered 1 liter of he-
tastarch intraoperatively to patients assigned to the study group and 1 liter
of albumin to patients assigned to the control group. All patients received
the remaining standard operative regimen of crystalloids and blood prod-
ucts at the discretion of the anesthesiologist. After the first liter of colloid
was administered, the patient received only albumin if more colloid was
needed to meet additional requirements for fluid replacement. All patients
were transferred postoperatively to the intensive care unit (ICU). The at-
tending intensivists were blinded to the randomization. No hetastarch
was administered postoperatively in the ICU.
Clinical Protocol
Operative procedures were performed by teams involving 11 anesthesi-
ologists and 5 surgeons. The surgeons had between 3 and 8 years experience
performing OPCAB.
Patients undergoing planned elective procedures were prepared follow-
ing our hospital’s standard protocol. The elective operations were scheduled
at lease 1 week after the last preoperative dose of clopidogrel bisulfate (Pla-
vix; Sanofi-Aventis, Bridgewater, NJ). Plavix was reinitiated no earlier than
24 hours postoperatively at the physicians’ discretion.No aspirinwas admin-
istered during the final 24 preoperative hours. All patients were administered
aspirin beginning 7 hours postoperatively. Anesthesiologists in our facility
routinely use protamine to reverse the anticoagulant effects of heparin.
Postoperative fluid management, including blood product transfusion and
replacement of crystalloids and albumin to maintain adequate blood pressure,
cardiac index, and urine output, was performed at the discretion of the attend-
ing intensivist according to the clinical status of each patient. No attempt was
made to implement rigorous thresholds for postoperative fluid replacement,
that is, this study had no protocol for postoperative fluid replacement.
Information Collected
We prospectively collected the following demographic and preoperative
data for all patients: age, gender, body mass index (BMI), urgency of sur-
gery, serum albumin level, serum creatinine level, blood urea nitrogen level,
hematocrit, platelet count, prothrombin time, and partial thromboplastin
time, as well as preoperative administration of anticoagulants, antiplatelet
medications, and thrombolytic agents. The scale we used to categorize the
procedural urgency of the bypass differentiates elective procedures, urgent
procedures performed in the same hospitalization as the cardiac catheteriza-
tion, and urgent procedures performed as soon as possible after the cardiac
catheterization. Perioperative data included the identity of the surgeon and
anesthesiologist; patients’ lowest body temperature and highest activated
clotting time; and volume of crystalloids, colloids, and cell saver, and num-
ber of units of blood products administered. Postoperative measurements in-
cluded the hourly chest tube drainage in the first 12 postoperative hours; the
volume of crystalloid and albumin delivered and the number of units of
blood products transfused, all for the first 24 hours postoperatively; and
any reoperation of the chest to treat postoperative bleeding. We also re-
corded the duration of mechanical ventilation, duration of the stay in the
ICU, total length of the hospital stay, and mortality in the ICU and during
the total in-hospital stay.
Clinical Practices
With the exception of the choice of the fluid used for intraoperative vol-
ume replacement, all aspects of the care of patients in our study were left to
the discretion of the attending physicians. Nonetheless, all of this care con-
formed to certain institutional practice patterns. Activated clotting time was
used by the attending physicians to guide normalization during the proce-
dure. Cell saver was used for all patients. Heparin was reversed by prot-
amine at the end of all procedures. The determination of postoperative
hemoglobin, initiation, and volume of postoperative red blood cell transfu-
sion was left to the discretion of the attending intensivists involved ingery c September 2009
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viding postoperative care were kept blind to whether the patient had re-
ceived hetastarch for intraoperative volume replacement. Only albumin
was used for postoperative volume replacement. The initiation and volume
of postoperative volume replacement were at the discretion of the attending
intensivists.
Analytic Methods
We used the Fisher’s exact test or Student t test for independent samples
to conduct bivariate comparisons of study group measures with control
group measures as appropriate given the nature of the measurement. We
used analysis of covariance with general linear modeling and calculation
of linear regression slopes to conduct multivariate comparisons of interval
level-dependent measures between these groups while controlling for cova-
riates.We usedmultiple logistic regression and calculation of slopes (logs of
the odds ratio that can be treated within certain constraints as an estimate of
the relative risk) to make similar comparisons for dependent variables mea-
sured at the nominal (specifically binary) level. For logistic regression, we
used the omnibus test of model coefficients to summarize the statistical sig-
nificance of the odds ratios modeled in the logistic regression equation as
a whole. We used slopes and associated confidence intervals to model the
associations for both the analysis of covariance and logistic regression. In
addition to the analysis of statistical significance and modeling discussed
above, the difference between the study and control groups was compared
with the range of equivalence using confidence intervals constructed around
marginal means that had been estimated to adjust for covariates. We con-
ducted all analyses by intention to treat. After the exclusion of 4 subjects
converted to on-pump procedures for medical reasons, all analyses of asso-
ciations with the primary end point and key secondary outcomes were con-
ducted on complete data from all randomized study participants (ie, the
analysis of collected study data was identical to analysis by intention to
treat). Virtually complete data collection on all subjects made it unnecessary
to carry any observations forward or make any of the other adjustments that
can be called for by intention-to-treat analyses). Analyses were conducted
using Version 13.0.1 of SPSS for Windows (SPSS, Chicago, IL). We ap-
plied the false discovery rate (FDR) approach to analyses of the associations
of multiple outcomes with the (randomly assigned) replacement fluid to
control for the expected number of false-positive findings resulting from an-
alyzing the association of common (ie, shared) predictors with multiple po-
tential outcomes.28 An explanation of the FDR procedure, the formula for
adjusting target P values in accord with the FDR method, and the set of P
values used in this study are shown in Appendix 1. Particular statistical re-
sults are reported in the text only when those same results have not been re-
ported in one of this article’s results tables (Tables 1–3).
Target Outcomes
The study’s primary outcome measures were the numbers of units of
packed red blood cells, units of fresh-frozen plasma, and units of platelets
transfused within the first 24 hours after surgery. These were chosen as pri-
mary end points because of known risks associated with transfusion of
blood products. (The first 24 hours after surgery are also termed ‘‘POD
1’’ in the text below.) Secondary outcome measures included volume of
chest tube drainage within the first 12 postoperative hours, frequency of re-
operation for bleeding complications, duration of mechanical ventilation,
length of stay in the ICU, length of total postoperative hospital stay, and
total mortality rate. Chest-tube drainage was tracked over only the first
12 hours postoperatively because drainage in that period is most likely to
reflect postoperative bleeding, whereas drainage occurring later may also
reflect overall fluid overload and other processes leading to serous drainage.
Safety Monitoring Procedures
We aggressively monitored patient safety and any increase in adverse
events associated with either or both of the trial arms. We establishedThe Journal of Thoracic and Ca Data Safety Monitoring Committee. To ensure a clear cutoff point, we ar-
bitrarily defined severe postoperative bleeding as chest tube drainage ex-
ceeding 1000 mL of blood in the first 12 postoperative hours. The study
protocol called for the committee to meet after the first 15 patients reached
this 1000-mL threshold value. We chose chest tube drainage to define the
threshold for Data and Safety Monitoring Committee (DSMC) review be-
cause this drainage can be readily and unambiguously measured in a busy
ICU, and because it is less subject to physician practice patterns than are
the transfusion practices that are our study’s primary outcome.29 At that
DSMC meeting, the committee was charged with evaluating the interim
findings to determine whether either fluid carried an unacceptably increased
risk of postoperative bleeding. Standard inferential tests for independent
samples were used to compare relevant outcome rates for the hetastarch
and albumin groups. Protocol called for repeat meetings of the DSMC after
each 15 additional episodes of severe bleeding or earlier if investigators or
the patients’ referring clinicians raised questions about either of the arms
carrying increased risk. Question was raised in our study after the first
DSMC meeting when 2 additional subjects had drainage above the thresh-
old level. Findings of analyses conducted for the DSMC indicated a statisti-
cally significant difference in postoperative drainage rates, and study
recruitment was halted at that point. This safety monitoring process led to
recruitment being halted before the full target sample size was reached. De-
spite this early end of enrollment before reaching the target sample size set
by the statistical power analysis presented above, the study recruited an ad-
equate sample size to demonstrate statistically significant associations with
the primary end point and several of the secondary outcomes after using the
FDR technique to adjust (ie, increase) the target significance levels for mul-
tiple tests against the same outcomes.28
RESULTS
A total of 156 patients were enrolled in the study. Se-
venty-eight patients each were randomly assigned to the
study (hetastarch) and control (albumin) groups. Four other
patients were excluded after randomization because they
were converted to on-pump surgery. Data collected from
these 4 patients have been excluded from all data analyses.
Conduct of the study did not deviate from the protocol or
from any other aspects of the study design. Study recruit-
ment was halted by the Data Safety Monitoring Committee,
as noted above.
Table 1 summarizes the demographic and clinical charac-
teristics of all patients included in the study. There were no
statistically significant differences between the study and
control groups in any of the baseline characteristics.
The study and control groups were comparable with re-
spect to all perioperative variables except the highest acti-
vated clotting time, which was higher in the control group
(hetastarch 450.3 vs albumin 493.6, P ¼ .022) and the vol-
ume of colloid administered, which was higher in the study
group (hetastarch 1479.5 vs albumin 1192.3, P<.001) (Ta-
ble 2). The median urgency of the operative procedure was 1
(elective) both in the sample as a whole and within the study
and control groups. The difference in urgency between the
study and control groups was not statistically significant
(median text c2 with Yates’ continuity correction ¼ 0.646,
df ¼ 1, P ¼ .42, not significant). Care was provided by 11
anesthesiologists and 5 surgeons. No statistically significant
association was observed between the randomizationardiovascular Surgery c Volume 138, Number 3 705
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Hetastarch mean (SD) n* Albumin mean (SD) n* Statistical test test result (df) P value
Age, y 64.1 (9.8) n ¼ 78 64.4 (9.0) n ¼ 78 Student t test ¼ 0.229 (df ¼ 154) .82, NS
Sex, male 82.1% n ¼ 78 70.5% n ¼ 78 Fisher’s exact test .13, NS
Body mass index 27.5 (4.8) n ¼ 78 28.9 (5.3) n ¼ 78 Student t test ¼ 1.65 (df ¼ 154) .10, NS
Serum albumin level (g/dL) 3.75 (0.39) n ¼ 59 3.69 (0.47) n ¼ 63 Student t test ¼0.83 (df ¼ 120) .41, NS
Serum creatinine level (mg/dL) 1.11 (0.31) n ¼ 78 1.10 (0.33) n ¼ 78 Student t test ¼0.23 (df ¼ 154) .82, NS
Serum urea nitrogen level (mg/dL) 19.76 (8.61) n ¼ 78 18.32 (6.91) n ¼ 78 Student t test ¼1.15 (df ¼ 154) .25, NS
Hematocrit (%) 40.26 (4.18) n ¼ 78 40.22 (4.39) n ¼ 78 Student t test ¼0.052 (df ¼ 154) .96, NS
Platelet count (3103/mL) 228.96 (58.30) n ¼ 78 230.74 (66.07) n ¼ 78 Student t test ¼ 0.18 (df ¼ 154) .86, NS
Prothrombin time (INR) 1.47 (2.12) n ¼ 78 1.07 (0.10) n ¼ 78 Student t test ¼1.65 (df ¼ 77.35) .10, NS
Activated partial thromboplastin time (s) 38.56 (36.11) n ¼ 78 33.02 (15.73) n ¼ 78 Student t test ¼1.24 (df ¼ 105.21) .22, NS
Preoperative use of intravenous heparin 24.4% n ¼ 78 30.8% n ¼ 78 Fisher’s exact test .47, NS
Preoperative use of low-molecular-weight heparin 15.4% n ¼ 78 14.1% n ¼ 78 Fisher’s exact test 1.00, NS
Preoperative use of glycoprotein IIb/IIIa inhibitors 10.3% n ¼ 78 12.8% n ¼ 78 Fisher’s exact test .80, NS
Preoperative use of platelet inhibitors 3.8% n ¼ 78 11.5% n ¼ 78 Fisher’s exact test .13, NS
Preoperative use of warfarin 1.3% n ¼ 78 1.3% n ¼ 78 Fisher’s exact test 1.00, NS
Preoperative use of thrombolytic agents 3.8% n ¼ 78 1.3% n ¼ 78 Fisher’s exact test .62, NS
NS, Not significant; INR, international normalized ratio; SD, standard deviation. *n ¼ 78 in all cells unless otherwise noted.assignment and the identity of the participating surgeon or
anesthesiologist.
Primary Outcomes
Bivariate analyses showed that the study group had in-
creased transfusion requirements for all blood products on
POD 1: red blood cells (1.14 vs 0.40 units, P ¼ .018),
fresh-frozen plasma (0.57 vs 0.15 units, P ¼ .009), and
platelets (0.35 vs 0.10 Super-packs, P ¼ .014), all statisti-
cally significant (full statistical results readily available on
request). The study group also had a higher overall likeli-
hood of receiving a transfusion on POD 1 (46.2% vs
25.6%, P ¼ .012). The results of multivariate analyses ex-
amining the association of hetastarch use with outcomes
on POD 1, while controlling for age and BMI, are presented
in Table 3. The volume of red blood cells is associated with
hetastarch (P ¼ .006) and age (P ¼ .0002). The volume of
colloid is associated with hetastarch (P< .0001). The num-
ber of packs of platelets transfused is associated with hetas-
tarch (P ¼ .014) and age (P ¼ .0023). The number of units706 The Journal of Thoracic and Cardiovascular Surof fresh-frozen plasma transfused is associated with hetas-
tarch (P ¼ .009) and age (P ¼ .001). The receipt of any
blood product on POD 1 is associated with hetastarch (P
¼ .008) and age (P ¼ 2 3 105). The ICU length of stay
is associated only with age (P ¼ .0006). The total hospital
length of stay is associated with age (P< 5 3 106) and
BMI (P ¼ .042). Of these associations, only the statistical
significance of the association of the total hospital length
of length of stay with BMI fails to satisfy the FDR threshold.
None of the predictors had any statistically significant asso-
ciations with cryoprecipitate use on POD 1, repeat opera-
tions to control bleeding, or hours of mechanical
ventilation. No study subject died before hospital discharge.
The adjusted intergroup differences on the primary and im-
portant secondary outcome measures all exceeded the equiv-
alence threshold.
Secondary Outcomes
Compared with controls (average ¼ 563.6 mL), the study
group (average 728.7 mL) had statistically significantlyTABLE 2. Intraoperative and baseline data for patients receiving hetastarch (study group) or albumin (control group)
Hetastarch mean (SD)* Albumin mean (SD)* Statistical test, test result, df P value
Lowest body temperature (C) 35.6 (0.58) 35.6 (0.54) Student t test ¼0.93, df ¼ 154 .35, NS
Highest activated clotting time (sec) 450.3 (85.48) 493.6 (141.00) Student t test ¼ 2.32, df ¼ 126.86 .022
Volume of crystalloid (mL) 2976.3 (1358.28) 3030.1 (988.06) Student t test ¼ 0.28, df ¼ 140.66 .78, NS
Volume of colloid (mL) 1479.5 (545.85) 1192.3 (303.99) Student t test ¼4.06, df ¼ 120.58 <.001
Cell saver (mL) 489.1 (403.25) 471.3 (331.66) Student t test ¼0.30, df ¼ 154 .76, NS
Red blood cells (No. of units) 0.44 (0.85) 0.38 (0.79) Student t test ¼0.39, df ¼ 154 .70, NS
Platelets (No. of 6-packs) 0.09 (0.37) 0.06 (0.37) Student t test ¼0.43, df ¼ 154 .67, NS
Fresh-frozen plasma (No. of units) 0.15 (0.70) 0.13 (0.59) Student t test ¼0.25, df ¼ 154 .81, NS
Cryoprecipitate (No. of units) 0.00 (0.00) 0.13 (1.13) Student t test ¼ 1.00, df ¼ 77.00 .32, NS
No. of grafts 3.55 (1.04) n ¼ 78 3.45 (0.91) n ¼ 77 Student t test ¼0.61, df ¼ 153 .54, NS
Urgency of the procedure (median) 1 1 Median test c2 with Yates’ continuity
correction ¼ 0.65, df ¼ 1
.42, NS
NS, Not significant; SD, standard deviation. *n ¼ 78 in all cells unless otherwise noted.gery c September 2009
TABLE 3. Outcome data for patients receiving hetastarch (study group) or albumin (control group)
Slope (95% CI) P value
I Intercept Corrected model
(3.96) F ¼ 6.928
0.11 (6.82) to (1.09) df ¼ 3152
S P ¼ .002 P ¼ .0002
771.624 F ¼ 12.765
(5.81) 374.55–1168.70 df ¼ 3152
.0002 P<2 3 10-7
1255.0 F ¼ 5.95
12.6 559.0–1951.0 df ¼ 3152
S P<.0005 P ¼ .0007
(0.219) F ¼ 7.27
0.003 (1.14) to 0.70 df ¼ 3152
0.64, NS 0.0001
(0.762) F ¼ 9.98
0.005 (2.19) to 0.67 df ¼ 3152
0.29, NS P<5 3 10-6
(1.04) F ¼ 0.60
0.07 (4.12) to 2.04 df ¼ 3152
0.51, NS P ¼ .62, NS
0.004 c2.d ¼ 36.45
P< .006 df ¼ 3
P ¼ 6 3 10-8
0.0 c2 ¼ 3.49
0.17, NS df ¼ 3
P ¼ .32, NS
134.25 F ¼ 1.15
2.09 (9.87) to 278.37 df ¼ 3152
0.07, NS P ¼ .33, NS
(2.00) F ¼ 4.69
0.07 (4.49) to 0.50 df ¼ 3152
0.12, NS P< .004
(1.53) F ¼ 8.01
2 (4.93) to 1.86 df ¼ 3152
0.37, NS P<6 3 105
N/A N/A
le; POD 1, postoperative day 1 (defined as the first 24 hours in
ginal averages adjusted for covariates. yEstimate of odds ratio
veloped by Benjamini in 1995 as the Bonferroni-type control.
la and target P values are shown in Appendix 1. dOmnibus test
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Statistical
Test Hetastarchz Age BM
Mean No. of units of
red blood cells transfused
on POD 1
1.13 (2.52) 0.40 (0.89) Univariate
ANCOVA
(0.08) 0.059 0.047,
78 78 (1.39) to (0.23) 0.03–0.09 (0.01) to
P ¼ .006 P ¼ .0002 P ¼ .11, N
Mean chest tube drainage
in first 12 h
728.7 (323.5) 563.6 (197.9) Univariate
ANCOVA
148.28 5.330 (13.955)
78 78 (228.96) to (67.60) 0.97–9.69 (22.10) to
0.0004 0.0169 .0009
Mean volume of
colloid (mL)
1479.5 (545.8) 1192.3 (304.0) Univariate
ANCOVA
286.35 4.2 (1.7)
78 78 (427.76) to (144.94) (3.4) to 11.9 (16.0) to
P< .0001 P ¼ .27, NS P ¼ .81, N
Mean No. of superpacks
(12-packs) of platelets
transfused on POD 1
0.35 (0.77) 0.13 (0.38) Univariate
ANCOVA
(0.23) 0.016 0.016
78 78 (0.41) to (0.041) 0.006–0.026 (0.035) to
P ¼ .014 0.0025 0.10, NS
Mean No. of units of
fresh-frozen plasma
transfused on POD 1
0.56 (1.24) 0.15 (0.56) Univariate
ANCOVA
(0.39) 0.031 (0.025)
78 78 (0.68) to (0.10) 0.016–0.047 (0.054) to
0.009 0.0001 0.10, NS
Mean No. of units
of cryoprecipitate
transfused on POD 1
0.38 (2.52) 0.13 (1.13) Univariate
ANCOVA
(0.27) .018 .01
78 78 (0.90) to 0.35 (0.02) to 0.05 (0.05) to
0.39, NS 0.29, NS 0.77, NS
Percentage of patients
who received blood
products on POD 1
46.2% 25.6% Logistic
regression
2.78y 1.10y 0.94y
78 78 1.30–5.94 1.06–1.15 0.86–1.02
0.008 0.00002 0.94, NS
Percentage of patients
who were returned to
the operating suite
for bleeding
3.8% 1.3% Logistic
regression
2.98 1.08 0.94
78 78 0.30–29.96 0.96–1.21 0.75–1.19
0.35, NS 0.19, NS 0.62, NS
Mechanical ventilation (h) 26.3 (126.54) 13.8 (29.47) Univariate
ANCOVA
(10.80) (1.31) (0.87)
78 78 (40.08) to 18.48 (2.89) to 0.27 (3.83) to
0.47, NS 0.10, NS 0.65, NS
ICU stay (d) 1.64 (0.98) 1.96 (2.10) Univariate
ANCOVA
0.28 0.05 .49
78 78 (0.23) to 0.79 0.02–0.08 (0.03) to
0.28, NS 0.0006 0.49, NS
Hospital stay (d) 7.69 (2.57) 8.53 (4.27) Univariate
ANCOVA
(0.10) .09 .07
78 78 (0.79) to 0.59 0.05–0.13 0.003–0.14
0.77, NS P<5 3 106 0.042
No. of patients who
died during hospital stay
0 0 N/A 0 0 0
ANOVA,Analysis of variance; ANCOVA, analysis of covariance; ICU, intensive care unit; BMI, bodymass index; SD, standard deviation;NS, not significant;N/A, not availab
the ICU after surgery or the total time spent in the ICU, whichever came first). Direct percentages, means, and standard deviations not adjusted for covariates. *Estimated mar
and 95% confidence interval for that estimate of the odds ratio. cStatistical significance was tested against target P values adjusted for multiple comparisons using the FDR de
All associations with hetastarch that are statistically significant by the above multivariate analyses remain so by comparison with the FDR target values. The Benjamini formu
of model coefficients. zn ¼ 78 in all cells unless otherwise noted.
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Perioperative Management Hecht-Dolnik et alhigher total drainage from chest tubes within the first 12
postoperative hours (P< .0002 by bivariate analysis). We
used analysis of covariance to control for the influence of
age and BMI. Analysis of covariance found the associations
of total 12-hour chest tube drainage with hetastarch (P<
.0004), BMI (P ¼ .0009), and age (P<.017) all statistically
significant (Table 3). All of these probabilities are below the
target thresholds set by FDR analysis and remain statistically
significant after controlling for multiple comparisons for
each outcome.
During the intraoperative period, the study group received
more colloid (average 1479.5 mL) than those who were ad-
ministered albumin (average 1192.3 mL, P<.001). The av-
erage activated clotting time during this period was 450.3
seconds in the study group and 493.6 seconds in the control
group, a statistically significant difference (P ¼ .022). No
other intergroup differences of measurements made during
the operative period were statistically significant or demon-
strated a trend (Table 2).
We examined the relation between risk of bleeding and
age, serum albumin level, creatinine level, and BMI (Table
3). We found that increased age is associated with increased
volumes of red blood cells (P¼ .0002), fresh-frozen plasma
(P ¼ .0001), and platelets transfused (P¼ .0025). Increased
BMI is not a statistically significant risk factor for any of the
bleeding outcomes. On consideration of use outcomes,
higher age is associated with prolonged stay in the ICU
(P ¼ .0006) and hospital (P<5 3 106). Age also demon-
strates a trend toward increased duration of mechanical ven-
tilation (P ¼ .10, NS). The association of BMI with total
length of stay is statistically significant (P¼ .042), but the re-
sults of the statistical significance test for that association do
not pass the FDR threshold. Multivariate analysis does not
find any of the associations between serum albumin level
and any of the targeted outcomes to be statistically signifi-
cant. As such, serum albumin level has been excluded from
the analyses described here.
DISCUSSION
Hetastarch is an inexpensive plasma expander. It is rou-
tinely used in many medical facilities for intraoperative
volume replacement in patients undergoing cardiac sur-
gery. Previous studies have found the intraoperative use
of hetastarch for volume replacement to be associated
with increased postoperative bleeding after on-pump car-
diac surgery (ie, CABG).1-4,7,9,10,11,15 Approximately
85% of the cardiac surgery in our facility follows a differ-
ent strategy and is now performed off pump (ie, OP-
CAB).22,23 Our randomized trial investigated the
equivalence of the risk of postoperative bleeding between
intraoperatively administered albumin and hetastarch in pa-
tients undergoing OPCAB. To our knowledge, our study is
the first randomized clinical trial designed to have adequate
statistical power to examine the risks associated with intra-708 The Journal of Thoracic and Cardiovascular Suroperative use of hetastarch for fluid replacement in patients
undergoing OPCAB as it is performed in regular clinical
practice. As such, we established and adhered to protocols
for selecting patients to whom hetastarch would be admin-
istered and the volume that would be administered. The
project data set aggregated key clinical data. Our conduct
of the study in a busy community cardiac operating room
without functioning comprehensive computerized clinical
information at the time we conducted the study limits the
amount of information we collected for the project dataset.
Additional information (eg, hemodynamic data) were
hand-abstracted prospectively from the routine clinical
records.
Previous studies examining volume replacement in OP-
CAB have not led to consensus regarding its safety. The
strength of these previous studies may have been limited
in part by aspects of their design. The sample sizes in
the previous published randomized trials have ranged
from 22 to 94.2,8,9 These negative randomized trials may
well have been underpowered because of these small sam-
ple sizes: The largest sample size in any of these random-
ized trials is less than 30% of the target sample size
indicated by the statistical power analyses we conducted
for our study (vide supra) and less than the overall (n ¼
200) sample size calculated in a previous review10 for stud-
ies to have 90% power at P less than .05 to detect a 10%
increase in blood loss above that reported by Boldt and col-
leagues.9
Our multivariate analyses of associations with the pri-
mary and secondary outcomes have statistically significant
results. Before these results, some may have assumed that
the increased bleeding associated with hetastarch adminis-
tration was related to pump use during cardiopulmonary
bypass use rather than to hetastarch.10,24-26 Our results in-
dicate rather that hetastarch carries a risk of increased
postoperative bleeding that is statistically and clinically
significant in patients undergoing OPCAB, coronary artery
bypass in which the operation is performed without car-
diopulmonary bypass. The statistical strength of each prin-
cipal comparison between the hetastarch and the albumin
groups is robust. The adjusted estimates and confidence
intervals around the intergroup differences for the primary
outcomes dependably fall outside the zone of equivalence.
These results remain statistically significant after all valid
adjustments for multiple comparisons.
We also examined whether preoperative thrombolysis or
international normalized ratio (INR) affected the volume
of postoperative bleeding. The volume of postoperative
bleeding is not associated with INR use (P ¼ .93, NS).
The association with preoperative thrombolysis demon-
strates a trend that only reaches borderline statistical signif-
icance if INR is excluded from the analysis (figures readily
available on request). Its inclusion has no effect on which as-
sociations reach or fail to reach statistical significance. Asgery c September 2009
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bolysis from the multivariate analyses (Table 3). No mem-
bers of the study or control groups were returned to the
operating room for control of postoperative bleeding. Return
to the operating room was at the discretion of the attending
intensivists and surgeons, as with other aspects of postoper-
ative care. In our facility, the criteria considered in the deci-
sion to return a patient to the operating room for bleeding
control post-CABG or OPCAB are the rate of bleeding,
the degree of hemodynamic instability, and the presence or
absence of correctable factors such as hypothermia and coa-
gulopathy.
The increased risk of postoperative bleeding associated
with the use of intraoperative hetastarch raises important
questions about the safety of its use in these patients. Our
study was not designed to investigate the mechanism under-
lying the increased risk of postoperative bleeding carried by
hetastarch. Authors have hypothesized that the increased
risk could result from 1 or more of several mechanisms: he-
tastarch precipitating some coagulation factors, making
them unavailable to the coagulation cascade; hetastarch
forming a complex with factor VIII and fibrinogen; the fibri-
noplastic effect; and hetastarch coating the platelet surface,
causing platelet damage.10,17
Please note in this context, however, that albumin is more
expensive than hetastarch and has been found to carry its
own risks.16,29 Even the need for colloid administration dur-
ing and after heart surgery is a subject of discussion. Further
clinical studies may need to be conducted to clarify whether
volume replacement needs in similar future patients would
be best served by administering only crystalloid.
Study Limitations
Our study has several limitations. It was conducted in
a single facility that was the only study location. A multicen-
tered study might help to strengthen our findings regarding
hetastarch safety by evaluating whether our findings resulted
from idiosyncrasies of our patient population or surgical
practices. Further, all patients in our study group were ad-
ministered 1 liter of hetastarch in the operating room. No
hetastarch was infused in the postoperative period to mem-
bers of the study group. No hetastarch was administered to
control group patients at any time during the study. As
such, our project data do not allow evaluation of any
threshold effect or dose-response association between the
volume of hetastarch administered and the occurrence or
volume of postoperative bleeding. Future studies will be
needed to investigate the questions of a possible threshold
effect or dose response between the volume of hetastarch
administered and the amount of postoperative bleeding.
Our study’s protocol specified only if hetastarch was to
be administered, the volume of hetastarch to be adminis-
tered, and certain key preoperative and postoperative clin-The Journal of Thoracic and Cical measurements. Other aspects of the preoperative and
postoperative care and data collection were left to the attend-
ing clinicians’ discretion. Study group patients were admin-
istered more colloid in the operating room than were control
group patients (a difference of 287 mL, P< .001). We hy-
pothesize that this difference may have been linked to in-
creased immediate hemodynamic instability in that group.
Because the anesthesiologists administering the fluid were
not blind to the volume replacement fluid that had been
used, this greater volume may have resulted from prophylac-
tic steps taken by the anesthesiologists. Future studies can
explore whether hetastarch use is linked to increased imme-
diate hemodynamic instability.
We took care to make this study methodologically sound
and robust, using the FDR technique to address the risk of
false conclusions associated with multiple comparisons28
and a DSMC to monitor this intervention’s risk. The results
reported here as statistically significant were reached after
the early termination of recruitment recommended by the
DSMC had resulted in its sample size being well below
that called for in study planning by our statistical power
analysis. All important results remain statistically significant
after application of the FDR adjustment of cut-points. Post-
operative transfusion and fluid replacement were managed
by the staff intensivists who were blinded to the
intraoperative fluid administration. Transfusion was admin-
istered not per protocol but in accord with the intensivists’
clinical judgment. That judgment in turn was based on
multiple factors including but not limited to the volume
of chest tube drainage and hematocrit. As such, the postop-
erative transfusion rates are an imperfect index of postop-
erative bleeding in this trial. This imperfection of
transfusion rates as an index of postoperative bleeding
has been found to be the case in other previous investiga-
tions.30 The consistency of our multiple measures of post-
operative fluid loss and replacement leaves us confident
that these results indicate that hetastarch use is associated
with clinically and statistically significant increased post-
operative bleeding.
CONCLUSIONS
Intraoperative administration of hetastarch carries an in-
creased risk of postoperative bleeding after OPCAB. Our
study found hetastarch to have clinically and statistically sig-
nificant associations with increases in the amount transfused
and the volume of postoperative bleeding in patients under-
going OPCAB. Differences in key outcomes between those
infused with hetastarch and those infused with albumin fell
outside the zone of equivalence. These differences also
passed the FDR statistical threshold designed to guard
against the risk of false-positive conclusions resulting from
performing multiple comparisons. Previous studies have
found hetastarch use to be associated with increased riskardiovascular Surgery c Volume 138, Number 3 709
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ducted on pump.1 Our study extends those findings to
off-pump OPCAB procedures. Our findings with respect
to the study’s primary outcomes are strong and definite.
Our results reported here combined with those earlier re-
sults thus raise serious questions about the advisability of
using hetastarch as the default volume expander in
CABG. Our study was not statistically powered for analy-
sis of the association between intraoperative fluids admin-
istered and other outcomes, such as length of mechanical
ventilation, length of ICU and hospital stay, and mortality
rates. Our findings with regard to these secondary out-
comes should therefore be regarded as exploratory. Our
findings with respect to the study’s primary outcomes are
stronger and more definite.
William Prince, MD, from the Department of Anesthesia, Kaiser
Permanente Medical Center at Summit Providence, Oakland, Cal-
ifornia, helped coordinate the study in the operating room and col-
lected data for the study. Michael W. Moore, MD, Daniel E.
Newbrun, MD, Clinson Tan, MD, Robert P. Olson, MD, Rolando
Arroyo, MD, Jayne E. Chu,MD, Faith J.McCormack, MD, JunOr-
lanes, BS, Westin B. Coble, PA-C, Patricia E. Patterson, PA-C,
Victor H. Lee, BS, and Hon Lee, MD, all from the Department
of Cardiovascular Surgery, Kaiser Permanente Medical Center at
Summit Providence, Oakland, California, recruited people into
the study and collected data for the study. Bruce Fireman, MS,
from the Division of Research, Kaiser-Permanente, participated
in the Data Safety Monitoring Committee.
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comparisons.29
The FDR approach adjusts the target significance levels
for each analysis in a series of analyses of the associations
of a set of shared predictors with a group of specified out-
comes so that the target significance level for the analysis
of the association of the predictors with each of these spec-ified outcomes can be treated as equivalent to the standard
significance level of P< .05. We used this technique to
set target significance levels for the associations of each of
the 3 predictors (ie, hetastarch, BMI, and age) with each of
the specified outcomes (eg, units of red blood cells trans-
fused in the first 24 hours postoperatively, chest tube drain-
age in the first 12 hours postoperatively, and so on).gery c September 2009
Hecht-Dolnik et al Perioperative ManagementLet H1, H2, . . . . ., Hm, be the hypotheses sharing certain
characteristics (eg, predictors). Let p(1), p(2), . . . p(m) be the
corresponding P values. Let p(1) p(2) . . . p(m) be the or-
dered P values. Denote by H(i) the null hypothesis corre-
sponding to P(i). Then define the following Bonferroni-type
multiple testing procedure:
let k be the largest i for which P(i)(i/m)q*
then reject all H(i) I ¼ 1, 2,. , k.
The target P threshold values generated by this procedure
for results equivalent to P< .05 by comparison for the cur-
rent study are as follows:The Journal of Thoracic and CComparison Target
1 .005
2 .009
3 .014
4 .018
5 .023
6 .027
7 .032
8 .036
9 .041
10 .045
11 .050ardiovascular Surgery c Volume 138, Number 3 711
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